ライフサイエンスコーパス: esophageal varices

1 r bleeding ulcers, two receiving therapy for esophageal varices).

2 tive intervention for patients with bleeding esophageal varices.

3 not be used to treat patients with bleeding esophageal varices.

4 raphic measurement and endoscopic grading of esophageal varices.

5 sophagoscopy for the detection and sizing of esophageal varices.

6 producible method of determining the size of esophageal varices.

7 n alone in patients with major bleeding from esophageal varices.

8 nd specificity in predicting the presence of esophageal varices.

9 strated high sensitivity in the detection of esophageal varices.

10 aphy in ACLD still remains the screening for esophageal varices.

11 this cirrhotic population, primarily due to esophageal varices.

12 eeding in patients with cirrhosis with large esophageal varices.

13 duals are at increased risk of cirrhosis and esophageal varices.

14 13 cirrhotic patients with actively bleeding esophageal varices.

15 lled, where 88 (39.5%; 95%CI: 33.0-45.9) had esophageal varices.

16 distinct entity from the more common distal esophageal varices.

17 PLWH) are at increased risk of cirrhosis and esophageal varices.

18 varices are encountered less frequently than esophageal varices.

19 initial screening test for identifying large esophageal varices.

20 hosis require endoscopic screening for large esophageal varices.

21 images from lymph nodes, the azygos vein, or esophageal varices.

22 invasive imaging and pressure measurement of esophageal varices.

23 ageal varices and new modalities to evaluate esophageal varices.

24 vanced liver disease predict the presence of esophageal varices.

25 ely to benefit from endoscopic screening for esophageal varices.

26 cholangitis (PSC) may develop and bleed from esophageal varices.

27 nt initial hemorrhage in those found to have esophageal varices.

28 lts in portal hypertension and bleeding from esophageal varices.

29 st common cause of UGIB (33.3%), followed by esophageal varices (13.3%).

30 , in a subgroup analysis of patients without esophageal varices, 2 mg/kg belapectin did reduce HVPG a

31 Most patients (75%) had esophageal varices, 21% were Child-B, and 29% had at lea

32 (1.95; 95% CI: 1.14-3.68) and development of esophageal varices (3.11; 95% CI: 1.57-10.65) were signi

33 ents presented with ascites, 13 (11.3%) with esophageal varices, 4 (3.5%) with hepatic encephalopathy

34 Amongst those with history of (h/o) esophageal varices 7(41.2%) did not receive octreotide.

35 5% CI, 0.1-0.3; P < 0.001), absence of large esophageal varices (aHR, 0.4; 95% CI, 0.2-0.9; P = 0.048

36 was designed to determine the prevalence of esophageal varices and assess the utility of clinical pa

37 atients with cirrhosis require screening for esophageal varices and for liver cancer.

38 to enroll patients in screening programs for esophageal varices and hepatocellular carcinoma.

39 rediction of variceal bleeding, treatment of esophageal varices and new modalities to evaluate esopha

40 For patients with cirrhosis with high-risk esophageal varices and no history of variceal hemorrhage

41 with 3,362 adults with cirrhosis with large esophageal varices and no prior history of bleeding, wit

42 tality in patients with cirrhosis with large esophageal varices and no prior history of bleeding.

43 e areas of endoluminal ultrasound imaging of esophageal varices and noninvasive pressure measurement

44 alyzed to identify independent predictors of esophageal varices and of moderate/large size varices.

45 Untreated patients with newly diagnosed esophageal varices and practicing gastroenterologists we

46 gnificantly and the pharmacologic therapy of esophageal varices and the prophylaxis of the initial va

47 ratory distress syndrome and hemorrhage from esophageal varices) and seven cases of cancer (one each

48 ers, and worsening liver disease (cirrhosis, esophageal varices, and deterioration in liver function)

49 significant number of gastric varices, peri-esophageal varices, and extraluminal pathology were iden

50 platelet count, higher alkaline phosphatase, esophageal varices, and smoking was developed to predict

51 Downhill esophageal varices are a distinct entity from the more c

52 Proximal or 'downhill' esophageal varices are a rare cause of upper gastrointes

53 ause the pathophysiology and hemodynamics of esophageal varices are not well understood.

54 logic disease were independent predictors of esophageal varices (area under the receiver operator cha

55 h-risk varices (HRV) were defined as grade 3 esophageal varices as well as grade 2 esophageal varices

56 atic decompensation (hepatic encephalopathy, esophageal varices, ascites, or portal hypertension) or

57 n analysis of a subgroup of patients without esophageal varices at baseline (n = 81), 2 mg/kg belapec

58 varices and we excluded 26 patients who had esophageal varices at baseline so that predictors of new

59 cally significant PH (HVPG >/= 10 mm Hg) and esophageal varices at high risk of bleeding.

60 Guidelines recommend an early diagnosis of esophageal varices before incident bleeding by screening

61 Emergency treatment of bleeding esophageal varices (BEV) consists mainly of endoscopic a

62 ely 90% sensitivity in the identification of esophageal varices determined to be large on endoscopy,

63 oscopic screening and surveillance to detect esophageal varices (EV) and prevent bleeding.

64 Esophageal varices (EV) are common in adults with Fontan

65 Esophageal varices (EV) bleeding in patients with hepato

66 ria are not appropriate to exclude high-risk esophageal varices (EV) in HCC patients, and endoscopy s

67 ients, EIS is usually performed for bleeding esophageal varices (EV) in infants with congenital bilia

68 e assessment of portal hypertension (PH) and esophageal varices (EV) in patients with cirrhosis.

69 From 2005 to 2012, patients with esophageal varices (EV) in the National Surgical Quality

70 rrhosis without (stage 1) and with (stage 2) esophageal varices (EV).

71 ; HVPG values correlate with the presence of esophageal varices (EV).

72 n either in isolation or in combination with esophageal varices (EV).

73 y significant portal hypertension (CSPH) and esophageal varices (EVs) in patients with compensated ci

74 s with low likelihood of harboring high-risk esophageal varices (EVs) or having clinically significan

75 tients with cirrhosis with moderate to large esophageal varices (EVs), the more cost-effective option

76 liver disease such as refractory ascites and esophageal varices for patients awaiting liver transplan

77 rsity of Florida- Jacksonville location with esophageal varices, gastric varices, or both seen on CT

78 In those with small esophageal varices, growth to LEVs was observed in 13%,

79 copic treatments for strictures and bleeding esophageal varices have been proposed and may improve ou

80 ESLD was defined as bleeding esophageal varices, hepatic encephalopathy, persistent a

81 NRH was defined as the presence of ascites, esophageal varices, hepatic encephalopathy, portal throm

82 ase severity were worse and the frequency of esophageal varices higher with increasing Ishak stage (P

83 um albumin (HR 0.97; 95% CI: 0.94-0.99), and esophageal varices (HR 1.70; 95% CI: 1.21-2.38) but not

84 lead to portal hypertension (PH), high-risk esophageal varices (HRV), and liver transplantation, des

85 Performance status, AST, abdominal pain, and esophageal varices improved the discriminatory ability o

86 atients showed no varices in 52 (34%), small esophageal varices in 28 (19%), large esophageal varices

87 njection for management of actively bleeding esophageal varices in cirrhotic patients.

88 ography (HRES) was used to image and measure esophageal varices in control subjects and patients with

89 Our aim was to determine the prevalence of esophageal varices in patients with PSC and the variable

90 However, the exact prevalence of esophageal varices in patients with PSC remains unknown

91 in the endoscopic and radiologic therapy of esophageal varices in the past few years.

92 remains unknown and potential predictors of esophageal varices in this population have not been iden

93 rty-six percent (102 of 283) of patients had esophageal varices including 56% (57 of 102) with modera

94 Bleeding esophageal varices is a deadly complication of liver cir

95 This update and review of esophageal varices is given in five sections: new develo

96 small esophageal varices in 28 (19%), large esophageal varices (LEVs) in 60 (40%), and gastric varic

97 ophagogastroduodenoscopy (EGD) screening for esophageal varices needing treatment (EVNT).

98 Portal hypertension and esophageal varices needing treatment could be predicted

99 t, and were case matched to patients without esophageal varices (NEV) based on sex, age, surgery type

100 and major risk factors for bleeding, such as esophageal varices or a low platelet count, are frequent

101 ence or absence of PH defined as presence of esophageal varices or ascites or low platelet count and

102 ns of portal hypertension, including grade 3 esophageal varices or grade 2 varices with red wale mark

103 ates and defined by the presence of ascites, esophageal varices, or hepatic encephalopathy, or when E

104 following clinical characteristics: ascites, esophageal varices, or total bilirubin greater than 2 mg

105 en patients with and those without high-risk esophageal varices (P = .09-.42).

106 T was independently associated with baseline esophageal varices (P = 0.01) and prothrombin time (P =

107 rget populations of the study were all adult esophageal varices patients who were on non-selective B-

108 esophageal variceal bleeding, screening for esophageal varices, prediction of variceal bleeding, tre

109 Hemorrhage from esophageal varices remains a substantial management prob

110 ly a result of portal hypertension, downhill esophageal varices result from vascular obstruction of t

111 re significantly less likely to rebleed from esophageal varices than patients receiving sclerotherapy

112 te analysis identified bilirubin, cirrhosis, esophageal varices, tumor size, and macrovascular invasi

113 ld undergo evaluation for, and treatment of, esophageal varices; upper endoscopy is suggested in the

114 ), new HCC, surveillance for or treatment of esophageal varices, variceal bleeding, all-cause hospita

115 been reported elsewhere that the presence of esophageal varices varies widely among cirrhotic patient

116 less than 150 x 10(3)/dL for the presence of esophageal varices was 6.3 (95% CI: 2.6-15.8).

117 The presence of esophageal varices was detected using endoscopic examina

118 eeding, encephalopathy, or jaundice) without esophageal varices was included, and 5-year outcome is r

119 eeding, encephalopathy, or jaundice) without esophageal varices was included, and 5-year outcome is r

120 The natural history of cirrhosis with esophageal varices was simulated using a Markov model.

121 Esophageal varices were encountered in 1 patient after w

122 Child-Pugh score, tumor number, and esophageal varices were independent predictors of surviv

123 Esophageal varices were prevalent among cirrhotic patien

124 Patients with bleeding esophageal varices were randomized into ligation or comb

125 l, 62 patients with cirrhosis with high-risk esophageal varices were randomized to propranolol (titra

126 Patients with cirrhosis and esophageal varices were studied before and after a build

127 s (ECOG PS) 0-1, and following management of esophageal varices, when present, according to instituti

128 Unlike the much more common distal esophageal varices, which are most commonly a result of

129 should be considered for patients with large esophageal varices who cannot tolerate beta-blockers.

130 in selecting patients at high risk of having esophageal varices who could benefit from the targeted e

131 rade 3 esophageal varices as well as grade 2 esophageal varices with red color signs or gastroesophag

132 upper endoscopy revealed multiple 'downhill' esophageal varices with stigmata of recent hemorrhage.

133 Child-Pugh class, or the presence/absence of esophageal varices with the postmeal delta increase in L

134 In patients with esophageal varices without bleeding, prophylaxis with va